DDIs between long-term treatments and HCQ
A total of 38 patients (62%) had a potential increased risk of QT
prolongation due to DDIs between their long-term treatments and HCQ.
Among them, 32 patients had at least one co-medication contraindicated
or not recommended with HCQ. The mean of co-medication contraindicated
or not recommended with HCQ per patient was 1.9
CI95% [1.48 to 2.27] and 10 patients had 3 or more
of these co-medications.
More precisely, 13/32 patients had a contraindicated drug with HCQ.
Drugs involved were amiodarone 5/13, escitalopram 5/13, fluconazole
1/13, hydroxyzine 1/13, and levofloxacine 1/13. Moreover, a drug that
could create a clinical or biological situation facilitating or inducing
QT prolongation (hypokalemia or bradycardia) was also a part of the long
term-treatments of 14/32 patients.
The other 6/38 patients only had a co-medication that could induce a
clinical situation at risk of QT prolongation.